PMID- 19120333
OWN - NLM
STAT- MEDLINE
DCOM- 20090422
LR  - 20090317
IS  - 1365-2133 (Electronic)
IS  - 0007-0963 (Linking)
VI  - 160
IP  - 3
DP  - 2009 Mar
TI  - Medium-dose ultraviolet (UV) A1 vs. narrowband UVB phototherapy in atopic eczema: 
      a randomized crossover study.
PG  - 652-8
LID - 10.1111/j.1365-2133.2008.08984.x [doi]
AB  - BACKGROUND: Ultraviolet (UV) A1 and narrowband (NB)-UVB have been reported to be 
      effective treatments for atopic eczema (AE). OBJECTIVES: We aimed to compare the 
      efficacy of medium-dose UVA1 and NB-UVB mono-phototherapy in patients with AE. 
      METHODS: A randomized double-blind controlled crossover trial (ClinicalTrials.gov 
      Identifier: NCT00419406) was conducted in which patients with AE received a 
      6-week course of both medium-dose UVA1 and NB-UVB. Clinical efficacy was assessed 
      using the Six Area, Six Sign, Atopic Dermatitis (SASSAD) score and a visual 
      analogue scale for pruritus. Assessment of health-related quality of life was 
      performed using the Skindex-29. Total immunoglobulin E (IgE) and eosinophilic 
      cationic protein (ECP) were evaluated at baseline and after each phototherapy 
      course. RESULTS: Twenty-eight patients who completed both UVA1 and NB-UVB 
      phototherapy courses on an intention-to-treat basis were analysed according to 
      the crossover design. Both interventions were associated with significant 
      clinical improvement but there was no significant difference between treatments 
      with respect to the mean +/- SD relative reduction (RR) of the clinical scores 
      (SASSAD, 43.7 +/- 31.4% vs. 39.4 +/- 24.1%, P = 0.5; pruritus score, 16 +/- 61.8% 
      vs. 25.2 +/- 30.5%, P = 0.5, respectively). There was no significant difference 
      in the mean +/- SD RR of the Skindex-29 after UVA1 and NB-UVB phototherapy (12.7 
      +/- 18.8% vs. 16.5 +/- 17.6%, P = 0.1). Changes in the total IgE and ECP levels 
      following UVA1 and NB-UVB did not differ significantly (P = 0.3 and P = 0.9, 
      respectively). CONCLUSIONS: A 6-week course of NB-UVB and UVA1 phototherapy of AE 
      resulted in significant clinical improvement. With regard to efficacy and 
      tolerability, both phototherapeutic modalities may be considered comparably good.
FAU - Gambichler, T
AU  - Gambichler T
AD  - Department of Dermatology, Ruhr-University of Bochum, Gudrunstr. 56, D-44791 
      Bochum, Germany. t.gambichler@klinikum-bochum.de
FAU - Othlinghaus, N
AU  - Othlinghaus N
FAU - Tomi, N S
AU  - Tomi NS
FAU - Holland-Letz, T
AU  - Holland-Letz T
FAU - Boms, S
AU  - Boms S
FAU - Skrygan, M
AU  - Skrygan M
FAU - Altmeyer, P
AU  - Altmeyer P
FAU - Kreuter, A
AU  - Kreuter A
LA  - eng
SI  - ClinicalTrials.gov/NCT00419406
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20081211
PL  - England
TA  - Br J Dermatol
JT  - The British journal of dermatology
JID - 0004041
RN  - 37341-29-0 (Immunoglobulin E)
RN  - EC 3.1.27.- (Eosinophil Cationic Protein)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Cross-Over Studies
MH  - Dermatitis, Atopic/immunology/*radiotherapy
MH  - Double-Blind Method
MH  - Eosinophil Cationic Protein/blood
MH  - Female
MH  - Humans
MH  - Immunoglobulin E/blood
MH  - Male
MH  - Middle Aged
MH  - Severity of Illness Index
MH  - Treatment Outcome
MH  - Ultraviolet Therapy/adverse effects/*methods
MH  - Young Adult
EDAT- 2009/01/06 09:00
MHDA- 2009/04/23 09:00
CRDT- 2009/01/06 09:00
PHST- 2009/01/06 09:00 [entrez]
PHST- 2009/01/06 09:00 [pubmed]
PHST- 2009/04/23 09:00 [medline]
AID - BJD8984 [pii]
AID - 10.1111/j.1365-2133.2008.08984.x [doi]
PST - ppublish
SO  - Br J Dermatol. 2009 Mar;160(3):652-8. doi: 10.1111/j.1365-2133.2008.08984.x. Epub 
      2008 Dec 11.